PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide:: First results in patients with meningiomas

被引:0
|
作者
Henze, M
Schuhmacher, J
Hipp, P
Kowalski, J
Becker, DW
Doll, J
Mäcke, HR
Hofmann, M
Debus, J
Haberkorn, U
机构
[1] Univ Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, D-6900 Heidelberg, Germany
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
[4] Hannover Med Sch, D-3000 Hannover, Germany
关键词
somatostatin receptors; DOTATOC; Ga-68; PET; meningioma;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging of somatostatin receptors (SSTRs) using [In-111]diethylenetriaminepentaacetic-acid-octreotide (DTPAOC) has proven to be helpful in the differentiation of meningiomas, neurinomas or neurofibromas, and metastases as well as in the follow-up of meningiomas, A drawback of the SPECT method is its limited sensitivity in detecting small meningiomas. Because of PET's increased spatial resolution and its ability to absolutely quantify biodistribution, a PET tracer for SSTR imaging would be desirable. Methods: 1,4,7,10-tetraazacyclododecane-N,N ' ,N "N ' ' ' -tetraacetic-acid-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) was labeled using the positron-emitting generator nuclide Ga-68. We acquired dynamic PET images over 120 min after intravenous injection of 175 MBq [Ga-68]DOTATOC in 3 patients suffering from 8 meningiomas (WHO I-o; 7- to 25-mm diameter). Patients' heads had been fixed using individually shaped fiber masks equipped with an external stereotactic localizer system to match PET, CT, and MRI datasets. Results: [68Ga]DOTATOC was rapidly cleared from the blood (half-life alpha, 3.5 min; half-life beta, 63 min). Standardized uptake values (SUVs) of meningiomas increased immediately after injection and reached a plateau 60-120 min after injection (mean SUV, 10.6). No tracer could be found in the surrounding healthy brain tissue. AH meningiomas (even the 3 smallest [7- to 8-mm diameter]) showed high tracer uptake and could be visualized clearly. Tracer boundaries showed a good correspondence with the matched CT and MRI images. PET provided valuable additional information regarding the extent of meningiomas located beneath osseous structures, especially at the base of the skull. Conclusion: According to our initial experiences, [Ga-68]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio.
引用
收藏
页码:1053 / 1056
页数:4
相关论文
共 50 条
  • [1] Characterization of 68Ga-DOTA-D-Phe1-Tyr3- octreotide kinetics in patients with meningiomas
    Henze, M
    Dimitrakopoulou-Strauss, A
    Milker-Zabel, S
    Schuhmacher, J
    Strauss, LG
    Doll, J
    Mäcke, HR
    Eisenhut, M
    Debus, J
    Haberkorn, U
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (05) : 763 - 769
  • [2] 68Ga-DOTA-Tyr3-octreotide-PET Imaging in intracranial meningiomas
    Putzer, D.
    Kendler, D.
    Madleitner, R.
    Gabriel, M.
    Bale, R. J.
    Sweeney, A. R.
    Uprimny, C.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S131 - S131
  • [3] PET-imaging of somatostatin receptors in small cell lung cancer with 68Ga-DOTA0-D-Phe1-Tyr3-octreotide. (DOTATOC).
    Henze, M
    Bischoff, H
    Schuhmacher, J
    Mäcke, HR
    Eisenhut, M
    Haberkorn, U
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 114P - 114P
  • [4] 68Ga-DOTAo-D phe1-tyr3-octreotide (DOTATOC):: A new PET-ligand for imaging somatostatin receptors in meningiomas.
    Henze, M
    Schuhmacher, J
    Hipp, P
    Kowalski, J
    Becker, DW
    Maecke, HR
    Debus, J
    Haberkorn, U
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 67P - 67P
  • [5] Modelling of 68Ga-DOTA0-D PHE1-TYR3-Octreotide (68Ga-DOTATOC) kinetics in patients with meningiomas
    Henze, M
    Milker-Zabel, S
    Dimitrakopoulou-Strauss, A
    Schuhmacher, J
    Strauss, LG
    Mäcke, HR
    Eisenhut, M
    Debus, J
    Haberkorn, U
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S234 - S235
  • [6] Therapy using labelled somatostatin analogues:: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
    Barone, Raffaella
    Walrand, Stephan
    Konijnenberg, Mark
    Valkema, Roelf
    Kvols, Larry K.
    Krenning, Eric R.
    Pauwels, Stanislas
    Jamar, Francois
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (03) : 283 - 290
  • [7] Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors
    Saenger, Philipp Wilhelm
    Freesmeyer, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (06) : 447 - 453
  • [8] Comparison of 68Ga-DOTA-Tyr3-Octreotide to 68Ga-DOTA-Lanreotide PET in NET patients
    Putzer, D.
    Waitz, D.
    Kroiss, A.
    Nilica, B.
    Kendler, D.
    Warwitz, B.
    Gradl, J.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S381 - S381
  • [9] Somatostatin Receptor PET in Neuroendocrine Tumors: 68Ga-DOTA-Tyr3-Octreotide vs. 68Ga-DOTA-Lanreotide
    Putzer, D.
    Kroiss, A.
    Waitz, D.
    Gabriel, M.
    Guggenberg, E.
    Uprimny, C.
    Decristoforo, C.
    Warwitz, B.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S273 - S273
  • [10] Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations
    Grassi, Elisa
    Sghedoni, Roberto
    Asti, Mattia
    Fioroni, Federica
    Salvo, Diana
    Borasi, Giovanni
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (02) : 176 - 182